BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI)

Q: What does CUSIP 09075P204 represent in this 13F holders report?

CUSIP 09075P204 is the security identifier for BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q3 2025?

35 institutional investors reported BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q3 2025. Use the holders table for investor-level position and value details.

CUSIP: 09075P204

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 21,847,524
Total 13F shares: 2,342,780
Share change: +1,724,696
Total reported value: $5,992,669
Price per share: $2.56
Number of holders: 35
Value change: +$4,499,749
Number of buys: 21
Number of sells: 12

Quarterly Holders Quick Answers

What is CUSIP 09075P204?
CUSIP 09075P204 identifies BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025
Previous quarter: Q2 2025

Recent filing periods for CUSIP 09075P204:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Top shareholders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Rashmi Agarwal	3/4/5	10%+ Owner	— class O/S missing	8,554,945	$187,267,747	—	03 Apr 2023	3/4/5
Vipin Agarwal	3/4/5	10%+ Owner	— class O/S missing	8,554,945	$187,267,747	—	03 Apr 2023	3/4/5
Indu R. Gupta	3/4/5	10%+ Owner	— class O/S missing	8,550,396	$187,168,169	—	03 Apr 2023	3/4/5
Tarun K. Gupta	3/4/5	10%+ Owner	— class O/S missing	8,550,396	$187,168,169	—	03 Apr 2023	3/4/5
Suganthi Balasubramanian	3/4/5	10%+ Owner	— class O/S missing	8,547,750	$187,110,248	—	03 Apr 2023	3/4/5
Anita Jain	3/4/5	10%+ Owner	— class O/S missing	8,547,300	$187,100,398	—	03 Apr 2023	3/4/5
Diwakar Jain	3/4/5	10%+ Owner	— class O/S missing	8,547,300	$187,100,398	—	03 Apr 2023	3/4/5
Krishnan Nandabalan	3/4/5	Director, 10%+ Owner	— mixed-class rows	8,840,750 mixed-class rows	$187,088,358	—	06 Apr 2023	3/4/5
Akrati Agarwal	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Alka Sood	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Anesha Agarwal	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Bina Jatin Patel	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
BioXcel Holdings, Inc.	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	25 Jun 2021	3/4/5
BioXcel LLC	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	25 Jun 2021	3/4/5
Jatin Markand Patel	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Krunal Dilip Patel	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Marshal D. Gibson	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Michael James Aiello	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Pardeep Kumar Sood	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
ARMISTICE CAPITAL, LLC	13D/G	—	5%	288,131	$564,737	-$9,229,922	31 Mar 2025	13D/G
OAKTREE CAPITAL MANAGEMENT LP	13F	Company	1.1%	241,188	$436,551	—	30 Jun 2025	13F
Murchinson Ltd.	13F	Company	0.37%	80,618	$145,919	—	30 Jun 2025	13F
DIVERSIFY WEALTH MANAGEMENT, LLC	13F	Company	0.07%	15,000	$102,000	—	30 Jun 2025	13F
Oaktree Fund Advisors, LLC	13F	Company	0.2%	42,913	$77,672	—	30 Jun 2025	13F
UBS Group AG	13F	Company	0.18%	39,882	$72,187	—	30 Jun 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.13%	28,182	$51,014	—	30 Jun 2025	13F
JONES FINANCIAL COMPANIES LLLP	13F	Company	0.12%	26,000	$46,020	—	30 Jun 2025	13F
HighTower Advisors, LLC	13F	Company	0.11%	24,600	$44,526	—	30 Jun 2025	13F
XTX Topco Ltd	13F	Company	0.11%	23,424	$42,397	—	30 Jun 2025	13F
Beacon Pointe Advisors, LLC	13F	Company	0.09%	18,845	$34,109	—	30 Jun 2025	13F
VANGUARD GROUP INC	13F	Company	0.09%	18,824	$34,071	—	30 Jun 2025	13F
BlackRock, Inc.	13F	Company	0.08%	17,778	$32,178	—	30 Jun 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.08%	16,919	$30,623	—	30 Jun 2025	13F
Oaktree Capital Group Holdings GP, LLC	13D/G	Oaktree Capital Holdings, LLC	2.7%	170,230	$28,939	-$434,154	31 Mar 2025	13D/G
CITADEL ADVISORS LLC	13F	Company	0.05%	11,378	$20,594	—	30 Jun 2025	13F
Matthew T. Wiley	3/4/5	Chief Commercial Officer	— mixed-class rows	28,386 mixed-class rows	$20,056	—	17 Sep 2024	3/4/5
OSAIC HOLDINGS, INC.	13F	Company	0.02%	5,053	$9,145	—	30 Jun 2025	13F
Vincent O'Neill	3/4/5	Executive Vice President, Chief of Product Development and Medical Officer	— mixed-class rows	24,438 mixed-class rows	$7,975	—	14 Dec 2024	3/4/5
MORGAN STANLEY	13F	Company	0.01%	1,580	$2,860	—	30 Jun 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.01%	1,547	$2,800	—	30 Jun 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.01%	1,370	$2,480	—	30 Jun 2025	13F
GROUP ONE TRADING LLC	13F	Company	0.01%	1,273	$2,304	—	30 Jun 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	879	$1,591	—	30 Jun 2025	13F
AllSquare Wealth Management LLC	13F	Company	0%	175	$317	—	30 Jun 2025	13F
Washington Trust Advisors, Inc.	13F	Company	0%	160	$290	—	30 Jun 2025	13F
RAYMOND JAMES FINANCIAL INC	13F	Company	0%	125	$226	—	30 Jun 2025	13F
Parkside Financial Bank & Trust	13F	Company	0%	112	$203	—	30 Jun 2025	13F
Zurcher Kantonalbank (Zurich Cantonalbank)	13F	Company	0%	103	$186	—	30 Jun 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	45	$81	—	30 Jun 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	44	$80	—	30 Jun 2025	13F

Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q3 2025

As of 30 Sep 2025, BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by 35 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,342,780 shares. The largest 10 holders included MILLENNIUM MANAGEMENT LLC, OAKTREE CAPITAL MANAGEMENT LP, FMR LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, XTX Topco Ltd, BlackRock, Inc., STATE STREET CORP, UBS Group AG, and Oaktree Fund Advisors, LLC. This page lists 35 institutional shareholders reporting positions in this security for the Q3 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

Q3 2025 holders

Holder diff

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 Value $	Q3 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.